Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrONTO Study: OCT-Guided Ranibizumab for Neovascular AMD
NCT00344227Phase 2Completed
- Sponsor
- University of Miami
- Start
- Aug 2004
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by University of Miami. Started Aug 2004; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00344227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00344227.